产品说明书

Hexaminolevulinate HCl

Print
Chemical Structure| 140898-91-5 同义名 : Hexyl 5-aminolevulinate hydrochloride;P-1206;Hexyl 5- aminolevulinate;5-Aminolevulinic Acid hexyl ester;Hexaminolevulinate (hydrochloride);5-Aminolevulinic acid hexyl ester hydrochloride;Hexaminolevulinate hydrochloride
CAS号 : 140898-91-5
货号 : A444075
分子式 : C11H22ClNO3
纯度 : 98%+
分子量 : 251.75
MDL号 : MFCD03695491
存储条件：

粉末 Inert atmosphere,Room Temperature

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 105 mg/mL(417.08 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 100 mg/mL(397.22 mM)，配合低频超声助溶
动物实验配方：
生物活性
描述 Hexaminolevulinate HCl is a fluorescent agent which has been approved for cystoscopic detection of papillary bladder cancer[3]. Clinical trials have shown that hexaminolevulinate (HAL) fluorescence cystoscopy improves the detection of bladder tumors compared with standard white-light cystoscopy, resulting in more efficacious treatment[4]. Exogenous administration of hexaminolevulinate induces fluorescent protoporphyrin IX (PpIX) accumulation preferentially in cancer cells. In some of the incubation conditions tested, the addition of DFO (deferoxamine) with HAL significantly increased PpIX 21 fluorescence of adherent monolayer cancer cells, but this was never the case for cells in suspension[5]. Blue light cystoscopy (BLC) with hexaminolevulinate during transurethral resection of bladder cancer improves detection of non-muscle-invasive bladder cancer (NMIBC) and reduces recurrence rates[6].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02800473 Bladder Cancer Not Applicable Completed - France ... 展开 >> Institut de Cancerologie de Lorraine Vandoeuvre-les-Nancy, France, 54519 收起 <<
NCT02857634 - Completed - France ... 展开 >> Groupement des Hôpitaux de l'Institut Catholique de Lille Lomme, Nord, France, 59462 收起 <<
NCT03058705 Bladder Cancer Not Applicable Completed - United States, New York ... 展开 >> University of Rochester Medical Center Rochester, New York, United States, 14642 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.97mL

0.79mL

0.40mL

19.86mL

3.97mL

1.99mL

39.72mL

7.94mL

3.97mL
参考文献

[1]Rose JB, Armstrong S, et al. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden. BJU Int. 2016 Jun;117(6B):E102-13.

[2]Garfield SS, Gavaghan MB, et al. The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation. Can J Urol. 2013 Apr;20(2):6682-9.

[3]Rose JB, Armstrong S, Hermann GG, Kjellberg J, Malmström PU. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden. BJU Int. 2016 Jun;117(6B):E102-13

[4]Di Stasi SM, De Carlo F, Pagliarulo V, Masedu F, Verri C, Celestino F, Riedl C. Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder. Ther Adv Urol. 2015 Dec;7(6):339-50

[5]Chan KM, Gleadle J, Vasilev K, MacGregor M. Probing Hexaminolevulinate Mediated PpIX Fluorescence in Cancer Cell Suspensions in the Presence of Chemical Adjuvants. Int J Mol Sci. 2020 Apr 22;21(8):2963

[6]Lotan Y, Bivalacqua TJ, Downs T, Huang W, Jones J, Kamat AM, Konety B, Malmström PU, McKiernan J, O'Donnell M, Patel S, Pohar K, Resnick M, Sankin A, Smith A, Steinberg G, Trabulsi E, Woods M, Daneshmand S. Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018. Nat Rev Urol. 2019 Jun;16(6):377-386